Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Posters/Exhibits/Break > Session
Posters/Exhibits/Break
Presentations
A1. ANTICOAGULATION CLINICS | |||||
|
(100) A QUALITATIVE STUDY OF WARFARIN SELF-MANAGEMENT IN THE UNITED STATES HEALTHCARE SYSTEM: INSIGHTS FROM PATIENT EXPERIENCES Spencer J. Gilbert1,2, Heeseung Hong1, Aubrey E. Jones1,2, Sara R. Vazquez1,2, Geoffrey D. Barnes3, Katelyn W. Sylvester4, Daniel M. Witt1,2. 1University of Utah College of Pharmacy, Salt Lake City, UT, USA 2University of Utah Health Thrombosis Service, Salt Lake City, UT, USA 3University of Michigan, Ann Harbor, MI, USA 4Brigham and Women's Hospital, Boston, MA, USA |
||||
A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION | |||||
|
(101) LOW-DOSE PLASMA-DERIVED VON WILLEBRAND FACTOR CONCENTRATE FOR SURGICAL PROPHYLAXIS IN EHLERS-DANLOS SYNDROME WITH NORMAL VWF PROFILES AND DESMOPRESSIN CONTRAINDICATIONS Joseph Stanco, Suchitra Acharya. Northwell Health, New Hyde Park, NY, and Cohen Children’s Medical Center, Queens, NY, USA |
||||
A4. DISORDERS OF PLATELET NUMBER OR FUNCTION | |||||
|
(102) HEPARIN INDUCED THROMBOCYTOPENIA IN CARDIAC SURGERY PATIENTS- A NATIONAL INPATIENT SAMPLE DATABASE STUDY FROM 2016-2021 Sruthi/P Ramanan1, Kalaivani Babu2, Srinishant Rajarajan2, Yin Yue3, Deep Shah1. 1AHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA 2Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA, USA 3Allegheny Health Network, Pittsburgh, PA, USA |
||||
A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS | |||||
|
(103) COAGULATION PARAMETERS AFTER ADMINISTRATION OF BT524, FIBRINOGEN CONCENTRATE FROM HUMAN PLASMA, FOR THE TREATMENT AND PROPHYLAXIS OF BLEEDING IN PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY: AN OPEN-LABEL PHASE I/III STUDY Claudia Djambas Khayat1, Amal El-Beshlawy2, Emna Gouider Belhadjali3, Abderrahim Khelif 4, Sonia Adolf5, Wolfgang Miesbach6, Heike Boehm7, Silke Aigner7, Salomon Abraha7, Fabian Bohlaender7, Joerg Schuettrumpf7,8. 1Department of Pediatrics, Hotel Dieu de France Hospital Beirut, Saint Joseph University, Beirut, Lebanon 2Pediatric Hospital CU, Egyptian Thalassemia Association, El Cairo, Egypt 3Hospital Aziza Othmana, Tunis, Tunisia 4Farhat Hached Hospital, Ibn El Jazzar Faculty of Medicine, Sousse University, Sousse, Tunisia 5National Research Center, Pediatric Hematology Department, El Cairo, Egypt 6Department of Hemostasis/Hemophilia Centre, Medical Clinic 2, University Hospital Frankfurt, Frankfurt, Germany 7Biotest AG, Dreieich, Germany 8Grifols, Barcelona, Spain |
||||
|
(104) CLOTTING POTENTIAL OF A NOVEL MESOPOROUS BIOACTIVE GLASS ABSORBABLE AND ANTIMICROBIAL HEMOSTATIC AGENT Keith A. Moskowitz1,2, Scott Janis2, Emily Alhassan2, John Waldo3, Mark Towler3, Pedro Abrantes4, Vanessa Jooste4, Brett Janis2. 1KA Bioscience Consultants, LLC, Westfield, IN, USA 2DesiCorp Inc., Louisville, KY, USA 3Missouri University of Science & Technology, Rolla, MO, USA 4University of the Western Cape, Cape Town, South Africa |
||||
A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS | |||||
|
(105) OUTCOMES OF MARSTACIMAB IN NORTH AMERICAN PARTICIPANTS WITH HEMOPHILIA A AND B WITHOUT INHIBITORS: SUBANALYSIS OF THE PHASE 3 BASIS TRIAL Anjali A1, Pengling 2, Jennifer 3, Travis 3, Andrew 4. 1Stead Family Department of Pediatrics, Carver School of Medicine, University of Iowa, Iowa City, IA, USA 2Pfizer Inc, Cambridge, MA, USA 3Pfizer Inc, New York, NY, USA 4Pfizer Inc, Collegeville, PA, USA |
||||
|
(106) EXPLORATORY ANALYSIS FROM HAVEN 1-4 TO FURTHER CONTEXTUALIZE INJECTION-SITE REACTIONS AMONG PEOPLE WITH HEMOPHILIA A RECEIVING EMICIZUMAB Maya Bloomberg1, Katherine Eakle2, Markus Niggli3, Christophe Dhalluin3, Lucy Lee2, Elise Lim2, Shannon L. Carpenter4. 1Sylvester Comprehensive Cancer Center, Miami, FL, USA 2Genentech, Inc., South San Francisco, CA, USA 3F. Hoffmann-La Roche Ltd, Basel, Switzerland 4Children’s Mercy Hospital, Kansas City, MT, USA |
||||
|
(107) IRON DEFICIENCY AND SYMPTOM BURDEN IN PATIENTS WITH HEAVY MENSTRUAL BLEEDING Mahalya Gogerly-Moragoda, MD1, Supreet Kaur Goraya, MPH, IBCLC2,3, Alice Ma, MD, FACP2,3, Callie Berkowitz, MD2,3. 1Internal Medicine Residency Program, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA 2Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA 3Blood Research Center, University of North Carolina, Chapel Hill, NC, USA |
||||
|
(108) PATIENT- AND CAREGIVER-REPORTED OUTCOMES WITH SUBCUTANEOUS MIM8 PROPHYLAXIS IN PEDIATRIC PATIENTS WITH HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS: PHASE 3 FRONTIER3 STUDY Gili Kenet1, Matteo Luciani2, Paula Kjöllerström3, Rubén Berrueco4, Amalie Rhode Høgh Nielsen5, Jay Jay Thaung Zaw5, Emily Waters6, Karin Fijn van Draat7, Ryan Rodriguez6. 1National Hemophilia Center and Institute of Thrombosis & Hemostasis, Sheba Medical Center, Tel Aviv, Israel 2Onco-Hematology, Cell and Gene Therapy and Bone Marrow Transplant Clinic Area, Bambino Gesù Children’s Hospital, Rome, Italy 3Pediatric Hematology Unit, Hospital Dona Estefânia, ULS São José, Lisbon, Portugal 4Pediatric Hematology Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain 5Novo Nordisk A/S, Søborg, Denmark 6Novo Nordisk Inc., Plainsboro, NJ, USA 7Department of Paediatric Haematology, Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands |
||||
|
(109) MAINTAINING FACTOR VIII TOLERANCE IN PATIENTS WITH SEVERE HEMOPHILIA A ON EMICIZUMAB: A FOUR-PATIENT CASE SERIES Emily E Mason, Amy Dunn. Nationwide Children's Hospital, Columbus, OH, USA |
||||
|
(111) INSIGHTS INTO EFFECTIVE IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A PATIENTS WITH INHIBITORS:NEW FINDINGS FROM THE INTERIM ANALYSIS OF THE MOTIVATE STUDY Robert F. Sidonio, Jr. 1, Carmen Escuriola Ettingshausen2. 1Associate Professor of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA 2HZRM Hämophilie Zentrum Rhein Main, Frankfurt, Germany |
||||
|
(112) ALTERED BASELINE FIBRINOLYTIC ACTIVITY IN LUNG CANCER PATIENTS: A FUNCTIONAL ASSESSMENT USING PLASMA LYSIS TIME AND FIBRINOLYTIC MARKERS Anuha Vellanki1, Prakash Kempaiah1, Alexander Pohlman1,2, Fakiha Siddiqui1, Walter Jeske 1, Debra Hoppensteadt1, Jeanine Walenga1, W.Keith Jones1, Jean Amiral1, Jawed Fareed1, Zaid Abdelsattar1. 1Loyola Univeristy Chicago, Maywood, IL, USA 2University of Illinois Chicago College of Medicine, Chicago, IL, USA |
||||
A7. PATHOPHYSIOLOGY OF THROMBOSIS | |||||
|
(113) THE POTENTIAL OF SILVER NANOPARTICLES AS ANTIBACTERIAL AGENTS IN THE MANAGEMENT OF VTE FOLLOWING PRE-ECLAMPSIA Manasvi Kondamudi1, Aarav Keskar1, Atul Laddu1, Jawed Fareed2. 1Global Thrombosis Forum, Suwanee, GA, USA 2Loyola University, Chicago, IL, USA |
||||
A8. ANTITHROMBOTIC THERAPY | |||||
|
(114) AI-DRIVEN DYNAMIC PATIENT AVATARS WITH RECURRENT THROMBOSIS AND INHERITED THROMBOPHILIA: A SCALABLE SIMULATION TOOL FOR PHYSICIAN TRAINING AND HANDOFF Anvi Agarwal1, Asmi Agarwal1, Elijah Eldrim2, Andrew Primous2, Yanhui Guo3, Ruchika Goel4,5, Richard Selinfreund6. 1McNeese P4 (Physician Preparatory Pathway Program), SIU School of Medicine, Springfield, IL, USA 2Medical Microbiology and Immunology, SIU School of Medicine, Springfield, IL, USA 3Department of Computer Science, University of Illinois Springfield, Springfield, IL, USA 4Division of Hematology/Oncology, Simmons Cancer Institute, SIU School of Medicine, Springfield, IL, USA 5Department of Pathology, Johns Hopkins University, Baltimore, MD, USA 6Departments of Medical Microbiology, Cell Biology and Immunology, and Medical Education, Springfield, IL, USA |
||||
|
(115) QUANTIFYING INAPPROPRIATE ANDEXANET ALFA USE PRIOR TO INSTITUTIONAL POLICY REVISION: A REVIEW OF FIFTY CONSECUTIVE ADMINISTRATIONS Alifya Altaf Lokhandwala, Filip Sadurski, Rohit Sharma, Monika Onusseit, Ellen Arrington, Sarah Benmir, Moosa Alhoda, Abdulrahman Alyounes Alayoub, Mishel Papali, Matthew Basciotta. Department of Medicine, Salem Hospital, Mass General Brigham, Salem, MA, USA |
||||
A9. INFORMATIONAL ABSTRACT (POSTER ONLY) | |||||
|
(117) DEVELOPMENT AND IMPLEMENTATION OF A SCREENING TOOL TO REDUCE BLEED RISK ASSOCIATED WITH ANTIPLATELET USE IN ANTICOAGULATION CLINIC PATIENTS Matthew J. DeSchepper, Jennifer Hardman, Megan Gallagher, Hannah Breidenbach, Michelle Te Ronde. Froedtert & the Medical College of Wisconsin, Milwaukee, WI, USA |
||||
|
(119) CASE REPORT OF A PEDIATRIC PATIENT WITH CONGENITAL FACTOR VII DEFICIENCY (4%) USING HUMAN RECOMBINANT FACTOR VIIA EPTACOG-BETA AS SECONDARY PROPHYLAXIS Ashley Wehrle1, Anuj Kaul1, Clayton Kubrick1, Nicoletta Machin1,2, Craig Seaman1,2, Frederico Xavier1,2. 1the Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA 2University of Pittsburgh, Pittsburgh, PA, USA |
||||